Drug Trial Radar · NCT05755789
Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal Surgery
Last checked: Nov 20, 2026Latest source record: Apr 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,000
Planned (sponsor's estimate)
Start
Jun 22, 2023
Primary completion
May 2025
Study completion Jun 2025
Sponsor
- Lead sponsor
- Poitiers University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this prospective, multicentre, double-blind, randomized clinical trial is to compare intermittent cefoxitin administration to loading bolus followed by continuous infusion for surgical antibiotic prophylaxis in colorectal surgery. The main objective is to demonstrate the superiority of a loading dose of cefoxitin followed by continuous infusion over standard of care boluses in reducing SSI within 30 days after colorectal surgery
Conditions
- Antibiotic Prophylaxis
- Colorectal Surgery
Interventions
Loading bolus of cefoxitinDrug
Cefoxitin \[2g\] before incision
Intermittent cefoxitinDrug
Additional bolus of cefoxitin \[1g\] every 2 hours until the end of surgical closure
Continuous infusion of placeboDrug
Continuous infusion of placebo from the end of the loading bolus until the end of surgical closure
Continuous infusion of cefoxitinDrug
Continuous infusion of cefoxitin \[0.5g/h\] from the end of the loading bolus until the end of surgical closure
Intermittent placeboDrug
Additional bolus of placebo every 2 hours until the end of surgical closure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Surgical site infectionTime frame: within 30 days after surgery
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
CHU Angers
Angers, France · Recruiting
Hopital privé Arras les Bonnettes
Arras, France · Recruiting
CHU Caen
Caen, France · Recruiting
CHU Clermont Ferrand
Clermont-Ferrand, France · Recruiting
CHU Grenoble
Grenoble, France · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
Hospices Civils Lyon
Lyon, France · Recruiting
Institut Paoli Calmettes
Marseille, France · Recruiting
CHRU Nancy
Nancy, France · Recruiting
CHU de Nantes
Nantes, France · Recruiting
Hopital Européen Gorges Pompidou
Paris, France · Recruiting
Clinique Mutualiste la Sagesse
Rennes, France · Recruiting
Hôpital Privé Rennais Cesson Sevigné
Rennes, France · Recruiting
CH St Brieuc
Saint-Brieuc, France · Recruiting
CHU St Etienne
Saint-Etienne, France · Recruiting
Hopitaux de Strasbourg
Strasbourg, France · Recruiting
CHU Toulouse Rangueil
Toulouse, France · Recruiting
CH Bretagne Atlantique vannes
Vannes, France · Recruiting
Centre Hospitalier de Poitiers
Poitiers, Vienne, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.